Loading
companiesCompany
Spectrum Pharmaceuticals
Spectrum Pharmaceuticals was a US cancer company that sold its haematology portfolio to Acrotech in 2019, won approval for the long-acting G-CSF eflapegrastim (Rolvedon) in 2022, and was acquired by Assertio in 2023.
Also called: Spectrum Pharmaceuticals, IncSpectrum Pharmaceuticals, Inc.
Overview
Spectrum Pharmaceuticals, latterly based in Boston after years in Henderson, Nevada, marketed a haematology portfolio (Zevalin, Folotyn, Beleodaq, Marqibo and Evomela) that it sold to Acrotech Biopharma in 2019 to concentrate on two development programmes: poziotinib, an EGFR and HER2 exon 20 inhibitor that received a complete response letter in 2022, and eflapegrastim (Rolvedon), a long-acting G-CSF for chemotherapy-induced neutropenia approved by the FDA in September 2022. Assertio Holdings acquired the company in 2023. It appears on OnCo as one of the most frequent industry sponsors of phase 3 cancer trials on the registry.
Headquarters
Boston, MA, US
Scorecard
All companies#121of 1244 companies, score 45
- approved products +18
- targets +6
- modalities +4
- regions +2
- registry trials +18
- failures -3
3 approved, 0 in phase 3, 0 earlier, 3 targets, 79 registry studies. Formula on the scorecards page.
Type
Stage
Acquired
Website
ApprovedPan-HDAC inhibitor (hydroxamate)
Belinostat · Beleodaq
Belinostat is an HDAC inhibitor for relapsed peripheral T-cell lymphoma; about a quarter of patients respond, and it can be used in patients with low platelets.
ApprovedAntifolate (DHFR inhibitor)
Pralatrexate · Folotyn
Pralatrexate was the first drug approved specifically for relapsed peripheral T-cell lymphoma; about a third of patients respond.
ApprovedLong-acting G-CSF fused to an antibody Fc fragment, once per chemotherapy cycle
Eflapegrastim · Rolvedon
Eflapegrastim is a once-per-cycle white cell growth factor approved in the United States in 2022 to prevent infections when chemotherapy for solid tumours knocks down neutrophils, an alternative to pegfilgrastim.
NegativeOral irreversible pan-HER tyrosine kinase inhibitor
Poziotinib was a tablet designed to fit the awkward shape of HER2 and EGFR exon 20 mutations in lung cancer. It shrank tumours in some patients but caused severe rash and diarrhoea, and the FDA declined to approve it in 2022.
Similar pages
- TrialTo Evaluate Efficacy of Belinostat or Pralatrexate in Combination Against CHOP Alone in PTCL
Shares Acrotech Biopharma, Belinostat, Pralatrexate.
- TrialRandomized Phase IIB Trial of Oral Azacytidine Plus Romidepsin Versus Investigator's Choice in PTCL
Shares Belinostat, Pralatrexate.
- TargetG-CSF receptor (CSF3R)
Shares Eflapegrastim, Neutropenia.
- CompanyBeyondSpring Pharmaceuticals
Shares Neutropenia, Non-small-cell lung cancer.
- CancerNodal T-follicular helper cell lymphoma, angioimmunoblastic type (angioimmunoblastic T-cell lymphoma)
Shares Belinostat, Pralatrexate, Neutropenia.
- TermWhat the NHS in England funds for lymphoma, appraisal by appraisal
Shares Belinostat, Pralatrexate.
cancers
fronts
drugs
ApprovedPan-HDAC inhibitor (hydroxamate)
Belinostat · Beleodaq
ApprovedLong-acting G-CSF fused to an antibody Fc fragment, once per chemotherapy cycle
Eflapegrastim · Rolvedon
NegativeOral irreversible pan-HER tyrosine kinase inhibitor
ApprovedAntifolate (DHFR inhibitor)
Pralatrexate · Folotyn
companies
terms
trials
A Study of Poziotinib in Patients With Epidermal Growth Factor Receptor (EGFR) or Human Epidermal Growth Factor Receptor 2 (HER2) Activating Mutations in Advanced MalignanciesA Study to Allow Continued Dosing and/or Follow-up of Patients Who Have Had Previous Exposure to PoziotinibA Study to Evaluate the Safety and Pharmacokinetics of Eflapegrastim in Pediatric Participants With Solid Tumors or Lymphomas and Treated With Myelosuppressive ChemotherapyStudy of Poziotinib in Participants With HER2-Positive Metastatic Breast Cancer